Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-04-25

AUTHORS

Stefano Kim, Bruno Buecher, Thierry André, Marine Jary, François-Clément Bidard, François Ghiringhelli, Éric François, Julien Taieb, Denis Smith, Christelle de la Fouchardière, Jérôme Desramé, Emmanuelle Samalin, Aurélie Parzy, Nabil Baba-Hamed, Olivier Bouché, David Tougeron, Laëtitia Dahan, Farid El Hajbi, Marion Jacquin, Magali Rebucci-Peixoto, Laurie Spehner, Véronique Vendrely, Dewi Vernerey, Christophe Borg

ABSTRACT

BACKGROUND: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating improved efficacy (12-month PFS of 47%) in the Epitopes-HPV02 trial. Antibodies targeting the checkpoint inhibitor (CKI) programmed cell death protein-1 (PD1) have demonstrated the efficacy as monotherapies in second-line treatment of SCCA. The aim of this study is to evaluate the combination of atezolizumab and mDCF as first-line chemotherapy in a non-comparative multicentre randomized phase II study of advanced SCCA patients. METHODS: Patients with chemo-naive advanced histologically proven SCCA, metastatic or unresectable locally advanced recurrence, and Eastern Cooperative Oncology Group-performance status (ECOG-PS) < 2 will be eligible. The primary endpoint is a 12-month PFS rate. Using one-arm non-parametric survival with unilateral alpha type I error of 5% and a statistical power of 80%, the upper critical value for the 12-month PFS rate is 47% to reject H0. Assuming 5% lost to follow-up, 99 patients will be randomized on a 2:1 basis, 66 to the experimental arm (arm A, mDCF plus atezolizumab) and 33 to the standard arm (arm B, mDCF). In both arms, 8 cycles of mDCF will be administered. In arm A, patients receive mDCF with a fixed dose of atezolizumab (800 mg every 2 weeks) and are followed up to 1 year. Secondary endpoints are overall survival, PFS, response rate, safety, health-related quality of life, and an extensive biomarker programme and its correlation with the treatment efficacy. DISCUSSION: Although the Epitopes-HPV02 trial has changed long-lasting prognosis of patients with SCCA in advanced stage disease, more than 50% of patients will progress at 12 months. The purpose of the SCARCE trial to establish the addition of atezolizumab to mDCF as a new standard in this rare disease. Associated biomarker studies and the control arm could contribute to better understanding of the potential synergic and tumour resistance mechanisms in SCCA. TRIAL REGISTRATION: NCT03519295. More... »

PAGES

352

Journal

TITLE

BMC Cancer

ISSUE

1

VOLUME

20

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-020-06841-1

DOI

http://dx.doi.org/10.1186/s12885-020-06841-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1127142698

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32334548


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anus Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Squamous Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Docetaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphatic Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive (FFCD), Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.476348.a", 
          "name": [
            "Department of Oncology, University Hospital of Besan\u00e7on, 3 Boulevard Alexander Flemingn, F-25030 Besan\u00e7on, France", 
            "H\u00f4pital Nord Franche Comt\u00e9, Montb\u00e9liard, France", 
            "Clinical Investigational Center, CIC-1431, University Hospital of Besan\u00e7on, Besan\u00e7on, France", 
            "INSERM, Unit 1098, University of Bourgogne Franche-Comt\u00e9, Besan\u00e7on, France", 
            "Groupe Coop\u00e9rateur Multidisciplinaire en Oncologie (GERCOR), Paris, France", 
            "F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive (FFCD), Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Stefano", 
        "id": "sg:person.0777665330.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777665330.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Curie, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.418596.7", 
          "name": [
            "Institut Curie, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buecher", 
        "givenName": "Bruno", 
        "id": "sg:person.01317547512.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317547512.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sorbonne Universit\u00e9 and H\u00f4pital Saint Antoine, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "Groupe Coop\u00e9rateur Multidisciplinaire en Oncologie (GERCOR), Paris, France", 
            "Sorbonne Universit\u00e9 and H\u00f4pital Saint Antoine, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Andr\u00e9", 
        "givenName": "Thierry", 
        "id": "sg:person.0724247022.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724247022.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Groupe Coop\u00e9rateur Multidisciplinaire en Oncologie (GERCOR), Paris, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Oncology, University Hospital of Besan\u00e7on, 3 Boulevard Alexander Flemingn, F-25030 Besan\u00e7on, France", 
            "H\u00f4pital Nord Franche Comt\u00e9, Montb\u00e9liard, France", 
            "Clinical Investigational Center, CIC-1431, University Hospital of Besan\u00e7on, Besan\u00e7on, France", 
            "INSERM, Unit 1098, University of Bourgogne Franche-Comt\u00e9, Besan\u00e7on, France", 
            "Groupe Coop\u00e9rateur Multidisciplinaire en Oncologie (GERCOR), Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jary", 
        "givenName": "Marine", 
        "id": "sg:person.01372020723.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372020723.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Curie, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.418596.7", 
          "name": [
            "Institut Curie, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bidard", 
        "givenName": "Fran\u00e7ois-Cl\u00e9ment", 
        "id": "sg:person.01134552110.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134552110.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Georges-Fran\u00e7ois Leclerc, Dijon, France", 
          "id": "http://www.grid.ac/institutes/grid.418037.9", 
          "name": [
            "Centre Georges-Fran\u00e7ois Leclerc, Dijon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghiringhelli", 
        "givenName": "Fran\u00e7ois", 
        "id": "sg:person.01131561444.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131561444.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Antoine-Lacassagne, Nice, France", 
          "id": "http://www.grid.ac/institutes/grid.417812.9", 
          "name": [
            "Centre Antoine-Lacassagne, Nice, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fran\u00e7ois", 
        "givenName": "\u00c9ric", 
        "id": "sg:person.01211341242.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211341242.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Europ\u00e9en Georges-Pompidou, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.414093.b", 
          "name": [
            "H\u00f4pital Europ\u00e9en Georges-Pompidou, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Taieb", 
        "givenName": "Julien", 
        "id": "sg:person.01203564254.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203564254.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France", 
          "id": "http://www.grid.ac/institutes/grid.42399.35", 
          "name": [
            "Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "Denis", 
        "id": "sg:person.01123502524.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123502524.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de la Fouchardi\u00e8re", 
        "givenName": "Christelle", 
        "id": "sg:person.01304763136.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304763136.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Priv\u00e9 Jean Mermoz, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.492693.3", 
          "name": [
            "H\u00f4pital Priv\u00e9 Jean Mermoz, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Desram\u00e9", 
        "givenName": "J\u00e9r\u00f4me", 
        "id": "sg:person.01275512465.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275512465.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut du Cancer de Montpellier, Montpellier, France", 
          "id": "http://www.grid.ac/institutes/grid.418189.d", 
          "name": [
            "Institut du Cancer de Montpellier, Montpellier, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samalin", 
        "givenName": "Emmanuelle", 
        "id": "sg:person.01171251146.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171251146.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Fran\u00e7ois Baclesse, Caen, France", 
          "id": "http://www.grid.ac/institutes/grid.418189.d", 
          "name": [
            "Centre Fran\u00e7ois Baclesse, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parzy", 
        "givenName": "Aur\u00e9lie", 
        "id": "sg:person.012735122143.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012735122143.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Groupe Hospitalier Paris Saint-Joseph, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.414363.7", 
          "name": [
            "Groupe Hospitalier Paris Saint-Joseph, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baba-Hamed", 
        "givenName": "Nabil", 
        "id": "sg:person.0624575614.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624575614.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Reims, Reims, France", 
          "id": "http://www.grid.ac/institutes/grid.139510.f", 
          "name": [
            "Centre Hospitalier Universitaire de Reims, Reims, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bouch\u00e9", 
        "givenName": "Olivier", 
        "id": "sg:person.01020263720.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020263720.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Poitiers, Poitiers, France", 
          "id": "http://www.grid.ac/institutes/grid.411162.1", 
          "name": [
            "Centre Hospitalier Universitaire de Poitiers, Poitiers, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tougeron", 
        "givenName": "David", 
        "id": "sg:person.0635311430.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635311430.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire La Timone, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "Centre Hospitalier Universitaire La Timone, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dahan", 
        "givenName": "La\u00ebtitia", 
        "id": "sg:person.0657643442.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657643442.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Oscar Lambret, Lille, France", 
          "id": "http://www.grid.ac/institutes/grid.452351.4", 
          "name": [
            "Centre Oscar Lambret, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hajbi", 
        "givenName": "Farid El", 
        "id": "sg:person.010720527517.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010720527517.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Canc\u00e9rop\u00f4le Grand-Est, Strasbourg, France", 
          "id": "http://www.grid.ac/institutes/grid.493837.2", 
          "name": [
            "Clinical Investigational Center, CIC-1431, University Hospital of Besan\u00e7on, Besan\u00e7on, France", 
            "Canc\u00e9rop\u00f4le Grand-Est, Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jacquin", 
        "givenName": "Marion", 
        "id": "sg:person.01217223066.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217223066.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Investigational Center, CIC-1431, University Hospital of Besan\u00e7on, Besan\u00e7on, France", 
          "id": "http://www.grid.ac/institutes/grid.411158.8", 
          "name": [
            "Department of Oncology, University Hospital of Besan\u00e7on, 3 Boulevard Alexander Flemingn, F-25030 Besan\u00e7on, France", 
            "Clinical Investigational Center, CIC-1431, University Hospital of Besan\u00e7on, Besan\u00e7on, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rebucci-Peixoto", 
        "givenName": "Magali", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM, Unit 1098, University of Bourgogne Franche-Comt\u00e9, Besan\u00e7on, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "INSERM, Unit 1098, University of Bourgogne Franche-Comt\u00e9, Besan\u00e7on, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spehner", 
        "givenName": "Laurie", 
        "id": "sg:person.011457426374.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011457426374.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France", 
          "id": "http://www.grid.ac/institutes/grid.42399.35", 
          "name": [
            "F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive (FFCD), Paris, France", 
            "Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vendrely", 
        "givenName": "V\u00e9ronique", 
        "id": "sg:person.01364426744.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364426744.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Methodology and Quality of Life in Oncology Unit, University Hospital of Besan\u00e7on, Besan\u00e7on, France", 
          "id": "http://www.grid.ac/institutes/grid.411158.8", 
          "name": [
            "INSERM, Unit 1098, University of Bourgogne Franche-Comt\u00e9, Besan\u00e7on, France", 
            "Methodology and Quality of Life in Oncology Unit, University Hospital of Besan\u00e7on, Besan\u00e7on, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vernerey", 
        "givenName": "Dewi", 
        "id": "sg:person.01125710150.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125710150.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive (FFCD), Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.476348.a", 
          "name": [
            "Department of Oncology, University Hospital of Besan\u00e7on, 3 Boulevard Alexander Flemingn, F-25030 Besan\u00e7on, France", 
            "H\u00f4pital Nord Franche Comt\u00e9, Montb\u00e9liard, France", 
            "Clinical Investigational Center, CIC-1431, University Hospital of Besan\u00e7on, Besan\u00e7on, France", 
            "INSERM, Unit 1098, University of Bourgogne Franche-Comt\u00e9, Besan\u00e7on, France", 
            "Groupe Coop\u00e9rateur Multidisciplinaire en Oncologie (GERCOR), Paris, France", 
            "F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive (FFCD), Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Borg", 
        "givenName": "Christophe", 
        "id": "sg:person.01153060003.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153060003.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12885-017-3566-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091351140", 
          "https://doi.org/10.1186/s12885-017-3566-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2015.20", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018025372", 
          "https://doi.org/10.1038/bjc.2015.20"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-04-25", 
    "datePublishedReg": "2020-04-25", 
    "description": "BACKGROUND: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating improved efficacy (12-month PFS of 47%) in the Epitopes-HPV02 trial. Antibodies targeting the checkpoint inhibitor (CKI) programmed cell death protein-1 (PD1) have demonstrated the efficacy as monotherapies in second-line treatment of SCCA. The aim of this study is to evaluate the combination of atezolizumab and mDCF as first-line chemotherapy in a non-comparative multicentre randomized phase II study of advanced SCCA patients.\nMETHODS: Patients with chemo-naive advanced histologically proven SCCA, metastatic or unresectable locally advanced recurrence, and Eastern Cooperative Oncology Group-performance status (ECOG-PS) <\u20092 will be eligible. The primary endpoint is a 12-month PFS rate. Using one-arm non-parametric survival with unilateral alpha type I error of 5% and a statistical power of 80%, the upper critical value for the 12-month PFS rate is 47% to reject H0. Assuming 5% lost to follow-up, 99 patients will be randomized on a 2:1 basis, 66 to the experimental arm (arm A, mDCF plus atezolizumab) and 33 to the standard arm (arm B, mDCF). In both arms, 8\u2009cycles of mDCF will be administered. In arm A, patients receive mDCF with a fixed dose of atezolizumab (800\u2009mg every 2\u2009weeks) and are followed up to 1\u2009year. Secondary endpoints are overall survival, PFS, response rate, safety, health-related quality of life, and an extensive biomarker programme and its correlation with the treatment efficacy.\nDISCUSSION: Although the Epitopes-HPV02 trial has changed long-lasting prognosis of patients with SCCA in advanced stage disease, more than 50% of patients will progress at 12\u2009months. The purpose of the SCARCE trial to establish the addition of atezolizumab to mDCF as a new standard in this rare disease. Associated biomarker studies and the control arm could contribute to better understanding of the potential synergic and tumour resistance mechanisms in SCCA.\nTRIAL REGISTRATION: NCT03519295.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12885-020-06841-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "Eastern Cooperative Oncology Group performance status", 
      "squamous cell carcinoma", 
      "PFS rates", 
      "checkpoint inhibitors", 
      "cell carcinoma", 
      "advanced recurrent squamous cell carcinoma", 
      "recurrent anal squamous cell carcinoma", 
      "anal squamous cell carcinoma", 
      "recurrent squamous cell carcinoma", 
      "cell death protein 1", 
      "combination of atezolizumab", 
      "dose of atezolizumab", 
      "addition of atezolizumab", 
      "second-line treatment", 
      "first-line chemotherapy", 
      "phase II study", 
      "advanced stage disease", 
      "health-related quality", 
      "prognosis of patients", 
      "death protein 1", 
      "tumor resistance mechanisms", 
      "SCCA patients", 
      "advanced recurrence", 
      "fluorouracil regimen", 
      "Secondary endpoints", 
      "II study", 
      "primary endpoint", 
      "standard arm", 
      "stage disease", 
      "overall survival", 
      "arm A", 
      "experimental arm", 
      "control arm", 
      "Biomarker Program", 
      "atezolizumab", 
      "rare disease", 
      "patients", 
      "treatment efficacy", 
      "response rate", 
      "improved efficacy", 
      "SCCA", 
      "biomarker studies", 
      "trials", 
      "mDCF", 
      "protein 1", 
      "regimen", 
      "efficacy", 
      "carcinoma", 
      "disease", 
      "type I", 
      "endpoint", 
      "resistance mechanisms", 
      "survival", 
      "treatment", 
      "arm", 
      "monotherapy", 
      "multicentre", 
      "chemotherapy", 
      "prognosis", 
      "recurrence", 
      "docetaxel", 
      "statistical power", 
      "PFS", 
      "cisplatin", 
      "dose", 
      "study", 
      "months", 
      "new standard", 
      "antibodies", 
      "anus", 
      "rate", 
      "inhibitors", 
      "status", 
      "safety", 
      "better understanding", 
      "aim", 
      "years", 
      "life", 
      "standards", 
      "correlation", 
      "mechanism", 
      "synergic", 
      "program", 
      "combination", 
      "purpose", 
      "addition", 
      "quality", 
      "understanding", 
      "cycle", 
      "values", 
      "basis", 
      "upper critical value", 
      "power", 
      "H0", 
      "critical value", 
      "Epitopes-HPV02 trial", 
      "non-comparative multicentre", 
      "advanced SCCA patients", 
      "Cooperative Oncology Group-performance status", 
      "Oncology Group-performance status", 
      "Group-performance status", 
      "one-arm non-parametric survival", 
      "non-parametric survival", 
      "unilateral alpha type I", 
      "alpha type I", 
      "cycles of mDCF", 
      "extensive biomarker programme", 
      "SCARCE trial", 
      "Associated biomarker studies", 
      "potential synergic", 
      "NCT03519295", 
      "advanced recurrent anal squamous cell carcinoma", 
      "non-comparative phase II SCARCE GERCOR trial", 
      "phase II SCARCE GERCOR trial", 
      "II SCARCE GERCOR trial", 
      "SCARCE GERCOR trial", 
      "GERCOR trial"
    ], 
    "name": "Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial", 
    "pagination": "352", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1127142698"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-020-06841-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32334548"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-020-06841-1", 
      "https://app.dimensions.ai/details/publication/pub.1127142698"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_856.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12885-020-06841-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-020-06841-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-020-06841-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-020-06841-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-020-06841-1'


 

This table displays all metadata directly associated to this object as RDF triples.

482 TRIPLES      22 PREDICATES      161 URIs      151 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-020-06841-1 schema:about N108def56b2294e2299c6a53b1025da6f
2 N1e9841ee504645e688db57f6bee8e450
3 N31207f0c32d347a3b495c278a43091bf
4 N496f625f83604f6a9388029f39ed1fa3
5 N7bc7dfb3b4cf4d09913a5c2bef76c10d
6 N8128b52f6bde44afbf4267a171aab99d
7 N84d65e0d2d2a4196ba80c479add47eec
8 N898a2d29032045c896dff03a75c67530
9 N914b38abf6274f2081fe7da59f4cc1a9
10 Nb4c0e6aaa4f74e19ab1e1e14dcaf4ac3
11 Nc81f4f8233df4f0ebd0c9b8d8b1b6685
12 Ncb9445fcd18a4037b77eebf879e52a7c
13 Nd7e65696ba0642a497a58829fb1290b5
14 Ne118febc92d84625bac86a79614854ce
15 Nf0e99c1cbf734198b30f88f9e05c2a4b
16 Nf0ed32df3daf4ab88d2632d5214a2b89
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N84ff22d8c9174c3689d80565003f0d38
20 schema:citation sg:pub.10.1038/bjc.2015.20
21 sg:pub.10.1186/s12885-017-3566-0
22 schema:datePublished 2020-04-25
23 schema:datePublishedReg 2020-04-25
24 schema:description BACKGROUND: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating improved efficacy (12-month PFS of 47%) in the Epitopes-HPV02 trial. Antibodies targeting the checkpoint inhibitor (CKI) programmed cell death protein-1 (PD1) have demonstrated the efficacy as monotherapies in second-line treatment of SCCA. The aim of this study is to evaluate the combination of atezolizumab and mDCF as first-line chemotherapy in a non-comparative multicentre randomized phase II study of advanced SCCA patients. METHODS: Patients with chemo-naive advanced histologically proven SCCA, metastatic or unresectable locally advanced recurrence, and Eastern Cooperative Oncology Group-performance status (ECOG-PS) < 2 will be eligible. The primary endpoint is a 12-month PFS rate. Using one-arm non-parametric survival with unilateral alpha type I error of 5% and a statistical power of 80%, the upper critical value for the 12-month PFS rate is 47% to reject H0. Assuming 5% lost to follow-up, 99 patients will be randomized on a 2:1 basis, 66 to the experimental arm (arm A, mDCF plus atezolizumab) and 33 to the standard arm (arm B, mDCF). In both arms, 8 cycles of mDCF will be administered. In arm A, patients receive mDCF with a fixed dose of atezolizumab (800 mg every 2 weeks) and are followed up to 1 year. Secondary endpoints are overall survival, PFS, response rate, safety, health-related quality of life, and an extensive biomarker programme and its correlation with the treatment efficacy. DISCUSSION: Although the Epitopes-HPV02 trial has changed long-lasting prognosis of patients with SCCA in advanced stage disease, more than 50% of patients will progress at 12 months. The purpose of the SCARCE trial to establish the addition of atezolizumab to mDCF as a new standard in this rare disease. Associated biomarker studies and the control arm could contribute to better understanding of the potential synergic and tumour resistance mechanisms in SCCA. TRIAL REGISTRATION: NCT03519295.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N2d1efc4a7d664be89fe7d053fa6cb86a
29 N8b4a0cb246af4889a3afe5ef4c4eb1b8
30 sg:journal.1024632
31 schema:keywords Associated biomarker studies
32 Biomarker Program
33 Cooperative Oncology Group-performance status
34 Eastern Cooperative Oncology Group performance status
35 Epitopes-HPV02 trial
36 GERCOR trial
37 Group-performance status
38 H0
39 II SCARCE GERCOR trial
40 II study
41 NCT03519295
42 Oncology Group-performance status
43 PFS
44 PFS rates
45 SCARCE GERCOR trial
46 SCARCE trial
47 SCCA
48 SCCA patients
49 Secondary endpoints
50 addition
51 addition of atezolizumab
52 advanced SCCA patients
53 advanced recurrence
54 advanced recurrent anal squamous cell carcinoma
55 advanced recurrent squamous cell carcinoma
56 advanced stage disease
57 aim
58 alpha type I
59 anal squamous cell carcinoma
60 antibodies
61 anus
62 arm
63 arm A
64 atezolizumab
65 basis
66 better understanding
67 biomarker studies
68 carcinoma
69 cell carcinoma
70 cell death protein 1
71 checkpoint inhibitors
72 chemotherapy
73 cisplatin
74 combination
75 combination of atezolizumab
76 control arm
77 correlation
78 critical value
79 cycle
80 cycles of mDCF
81 death protein 1
82 disease
83 docetaxel
84 dose
85 dose of atezolizumab
86 efficacy
87 endpoint
88 experimental arm
89 extensive biomarker programme
90 first-line chemotherapy
91 fluorouracil regimen
92 health-related quality
93 improved efficacy
94 inhibitors
95 life
96 mDCF
97 mechanism
98 monotherapy
99 months
100 multicentre
101 new standard
102 non-comparative multicentre
103 non-comparative phase II SCARCE GERCOR trial
104 non-parametric survival
105 one-arm non-parametric survival
106 overall survival
107 patients
108 phase II SCARCE GERCOR trial
109 phase II study
110 potential synergic
111 power
112 primary endpoint
113 prognosis
114 prognosis of patients
115 program
116 protein 1
117 purpose
118 quality
119 rare disease
120 rate
121 recurrence
122 recurrent anal squamous cell carcinoma
123 recurrent squamous cell carcinoma
124 regimen
125 resistance mechanisms
126 response rate
127 safety
128 second-line treatment
129 squamous cell carcinoma
130 stage disease
131 standard arm
132 standards
133 statistical power
134 status
135 study
136 survival
137 synergic
138 treatment
139 treatment efficacy
140 trials
141 tumor resistance mechanisms
142 type I
143 understanding
144 unilateral alpha type I
145 upper critical value
146 values
147 years
148 schema:name Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
149 schema:pagination 352
150 schema:productId N360fbfdfc5d346439df9ed3161936194
151 Na3e7f2549ed3428ab3aaa6db3955e661
152 Ndfd7548a515848a2a04471ca186e80c6
153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1127142698
154 https://doi.org/10.1186/s12885-020-06841-1
155 schema:sdDatePublished 2022-01-01T18:59
156 schema:sdLicense https://scigraph.springernature.com/explorer/license/
157 schema:sdPublisher Nd6eabdf59e574940871a5518d7f9fb6f
158 schema:url https://doi.org/10.1186/s12885-020-06841-1
159 sgo:license sg:explorer/license/
160 sgo:sdDataset articles
161 rdf:type schema:ScholarlyArticle
162 N108def56b2294e2299c6a53b1025da6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Survival Rate
164 rdf:type schema:DefinedTerm
165 N1204d451342f49db875fc283e0c4f206 rdf:first sg:person.01203564254.60
166 rdf:rest N8d517dfbe6404ce99e31abf1e6e35020
167 N17b1cbcb6c1249f298d8f619b36c6cf6 rdf:first sg:person.01275512465.52
168 rdf:rest Nb87c9e09622449e7ac19328b4904f89e
169 N1e9841ee504645e688db57f6bee8e450 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Male
171 rdf:type schema:DefinedTerm
172 N1ee2a9a6b1834aa6b001332ab0909fcf rdf:first sg:person.01217223066.09
173 rdf:rest Nf2e1003499a94d0eb6babc8033950e2d
174 N2d1efc4a7d664be89fe7d053fa6cb86a schema:volumeNumber 20
175 rdf:type schema:PublicationVolume
176 N31207f0c32d347a3b495c278a43091bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Aged
178 rdf:type schema:DefinedTerm
179 N360fbfdfc5d346439df9ed3161936194 schema:name doi
180 schema:value 10.1186/s12885-020-06841-1
181 rdf:type schema:PropertyValue
182 N39b95b2e51de4131a55bf4ab0efa3509 rdf:first sg:person.01131561444.16
183 rdf:rest Nd4849f88f9a74161a6a7412e111863f9
184 N3f5513a7e0b043daa2f1d518f7dc1e1c rdf:first sg:person.0635311430.72
185 rdf:rest N476ff727f4be4da781c1de3df8e45cce
186 N476ff727f4be4da781c1de3df8e45cce rdf:first sg:person.0657643442.84
187 rdf:rest Neb269ae2510546d7bf18ccc8a415c8bf
188 N496f625f83604f6a9388029f39ed1fa3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Follow-Up Studies
190 rdf:type schema:DefinedTerm
191 N5033b6e35f4743ec94bc55d3c0fe8cd6 rdf:first sg:person.011457426374.36
192 rdf:rest Nd0f02062c7ed4a3f994a11104d93d340
193 N59678c071e634ae6a0ec60d95159d2ce rdf:first sg:person.01304763136.25
194 rdf:rest N17b1cbcb6c1249f298d8f619b36c6cf6
195 N5d7ea6de43394988ac7f30047a7eae0a rdf:first sg:person.0624575614.78
196 rdf:rest Nb86fccc278f1423b9417277996db7473
197 N6dce35c777324dd585b449c32ba245f2 rdf:first sg:person.01134552110.75
198 rdf:rest N39b95b2e51de4131a55bf4ab0efa3509
199 N763951c267084449a446c5678d8c9cde rdf:first sg:person.01372020723.34
200 rdf:rest N6dce35c777324dd585b449c32ba245f2
201 N7bc7dfb3b4cf4d09913a5c2bef76c10d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Carcinoma, Squamous Cell
203 rdf:type schema:DefinedTerm
204 N8128b52f6bde44afbf4267a171aab99d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Fluorouracil
206 rdf:type schema:DefinedTerm
207 N84d65e0d2d2a4196ba80c479add47eec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Cisplatin
209 rdf:type schema:DefinedTerm
210 N84ff22d8c9174c3689d80565003f0d38 rdf:first sg:person.0777665330.43
211 rdf:rest Nc3f178b73aa44e4186093eae6146252e
212 N898a2d29032045c896dff03a75c67530 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Docetaxel
214 rdf:type schema:DefinedTerm
215 N8b4a0cb246af4889a3afe5ef4c4eb1b8 schema:issueNumber 1
216 rdf:type schema:PublicationIssue
217 N8d517dfbe6404ce99e31abf1e6e35020 rdf:first sg:person.01123502524.94
218 rdf:rest N59678c071e634ae6a0ec60d95159d2ce
219 N8dc1687ec0e840efad8199693ec45035 rdf:first sg:person.01153060003.44
220 rdf:rest rdf:nil
221 N914b38abf6274f2081fe7da59f4cc1a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Humans
223 rdf:type schema:DefinedTerm
224 Na3e7f2549ed3428ab3aaa6db3955e661 schema:name dimensions_id
225 schema:value pub.1127142698
226 rdf:type schema:PropertyValue
227 Nb4c0e6aaa4f74e19ab1e1e14dcaf4ac3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Neoplasm Recurrence, Local
229 rdf:type schema:DefinedTerm
230 Nb86fccc278f1423b9417277996db7473 rdf:first sg:person.01020263720.01
231 rdf:rest N3f5513a7e0b043daa2f1d518f7dc1e1c
232 Nb87c9e09622449e7ac19328b4904f89e rdf:first sg:person.01171251146.51
233 rdf:rest Ne571edaf4c1e429e8134e4a17481fb62
234 Nc3f178b73aa44e4186093eae6146252e rdf:first sg:person.01317547512.52
235 rdf:rest Ne18c2cabd80b4a329f226c03139d0a7e
236 Nc81f4f8233df4f0ebd0c9b8d8b1b6685 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
237 schema:name Lymphatic Metastasis
238 rdf:type schema:DefinedTerm
239 Ncb9445fcd18a4037b77eebf879e52a7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
240 schema:name Female
241 rdf:type schema:DefinedTerm
242 Nd0f02062c7ed4a3f994a11104d93d340 rdf:first sg:person.01364426744.53
243 rdf:rest Nfde83fb159724ef08472160904742162
244 Nd4849f88f9a74161a6a7412e111863f9 rdf:first sg:person.01211341242.65
245 rdf:rest N1204d451342f49db875fc283e0c4f206
246 Nd4e7d657ce554ab1a237c82aeb8dd20c schema:affiliation grid-institutes:grid.411158.8
247 schema:familyName Rebucci-Peixoto
248 schema:givenName Magali
249 rdf:type schema:Person
250 Nd6eabdf59e574940871a5518d7f9fb6f schema:name Springer Nature - SN SciGraph project
251 rdf:type schema:Organization
252 Nd7e65696ba0642a497a58829fb1290b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
253 schema:name Antineoplastic Combined Chemotherapy Protocols
254 rdf:type schema:DefinedTerm
255 Ndfd7548a515848a2a04471ca186e80c6 schema:name pubmed_id
256 schema:value 32334548
257 rdf:type schema:PropertyValue
258 Ne118febc92d84625bac86a79614854ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
259 schema:name Anus Neoplasms
260 rdf:type schema:DefinedTerm
261 Ne18c2cabd80b4a329f226c03139d0a7e rdf:first sg:person.0724247022.53
262 rdf:rest N763951c267084449a446c5678d8c9cde
263 Ne571edaf4c1e429e8134e4a17481fb62 rdf:first sg:person.012735122143.81
264 rdf:rest N5d7ea6de43394988ac7f30047a7eae0a
265 Neb269ae2510546d7bf18ccc8a415c8bf rdf:first sg:person.010720527517.51
266 rdf:rest N1ee2a9a6b1834aa6b001332ab0909fcf
267 Nf0e99c1cbf734198b30f88f9e05c2a4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
268 schema:name Antibodies, Monoclonal, Humanized
269 rdf:type schema:DefinedTerm
270 Nf0ed32df3daf4ab88d2632d5214a2b89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
271 schema:name Prognosis
272 rdf:type schema:DefinedTerm
273 Nf2e1003499a94d0eb6babc8033950e2d rdf:first Nd4e7d657ce554ab1a237c82aeb8dd20c
274 rdf:rest N5033b6e35f4743ec94bc55d3c0fe8cd6
275 Nfde83fb159724ef08472160904742162 rdf:first sg:person.01125710150.88
276 rdf:rest N8dc1687ec0e840efad8199693ec45035
277 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
278 schema:name Medical and Health Sciences
279 rdf:type schema:DefinedTerm
280 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
281 schema:name Oncology and Carcinogenesis
282 rdf:type schema:DefinedTerm
283 sg:journal.1024632 schema:issn 1471-2407
284 schema:name BMC Cancer
285 schema:publisher Springer Nature
286 rdf:type schema:Periodical
287 sg:person.01020263720.01 schema:affiliation grid-institutes:grid.139510.f
288 schema:familyName Bouché
289 schema:givenName Olivier
290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020263720.01
291 rdf:type schema:Person
292 sg:person.010720527517.51 schema:affiliation grid-institutes:grid.452351.4
293 schema:familyName Hajbi
294 schema:givenName Farid El
295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010720527517.51
296 rdf:type schema:Person
297 sg:person.01123502524.94 schema:affiliation grid-institutes:grid.42399.35
298 schema:familyName Smith
299 schema:givenName Denis
300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123502524.94
301 rdf:type schema:Person
302 sg:person.01125710150.88 schema:affiliation grid-institutes:grid.411158.8
303 schema:familyName Vernerey
304 schema:givenName Dewi
305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125710150.88
306 rdf:type schema:Person
307 sg:person.01131561444.16 schema:affiliation grid-institutes:grid.418037.9
308 schema:familyName Ghiringhelli
309 schema:givenName François
310 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131561444.16
311 rdf:type schema:Person
312 sg:person.01134552110.75 schema:affiliation grid-institutes:grid.418596.7
313 schema:familyName Bidard
314 schema:givenName François-Clément
315 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134552110.75
316 rdf:type schema:Person
317 sg:person.011457426374.36 schema:affiliation grid-institutes:grid.7429.8
318 schema:familyName Spehner
319 schema:givenName Laurie
320 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011457426374.36
321 rdf:type schema:Person
322 sg:person.01153060003.44 schema:affiliation grid-institutes:grid.476348.a
323 schema:familyName Borg
324 schema:givenName Christophe
325 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153060003.44
326 rdf:type schema:Person
327 sg:person.01171251146.51 schema:affiliation grid-institutes:grid.418189.d
328 schema:familyName Samalin
329 schema:givenName Emmanuelle
330 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171251146.51
331 rdf:type schema:Person
332 sg:person.01203564254.60 schema:affiliation grid-institutes:grid.414093.b
333 schema:familyName Taieb
334 schema:givenName Julien
335 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203564254.60
336 rdf:type schema:Person
337 sg:person.01211341242.65 schema:affiliation grid-institutes:grid.417812.9
338 schema:familyName François
339 schema:givenName Éric
340 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211341242.65
341 rdf:type schema:Person
342 sg:person.01217223066.09 schema:affiliation grid-institutes:grid.493837.2
343 schema:familyName Jacquin
344 schema:givenName Marion
345 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217223066.09
346 rdf:type schema:Person
347 sg:person.012735122143.81 schema:affiliation grid-institutes:grid.418189.d
348 schema:familyName Parzy
349 schema:givenName Aurélie
350 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012735122143.81
351 rdf:type schema:Person
352 sg:person.01275512465.52 schema:affiliation grid-institutes:grid.492693.3
353 schema:familyName Desramé
354 schema:givenName Jérôme
355 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275512465.52
356 rdf:type schema:Person
357 sg:person.01304763136.25 schema:affiliation grid-institutes:grid.418116.b
358 schema:familyName de la Fouchardière
359 schema:givenName Christelle
360 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304763136.25
361 rdf:type schema:Person
362 sg:person.01317547512.52 schema:affiliation grid-institutes:grid.418596.7
363 schema:familyName Buecher
364 schema:givenName Bruno
365 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317547512.52
366 rdf:type schema:Person
367 sg:person.01364426744.53 schema:affiliation grid-institutes:grid.42399.35
368 schema:familyName Vendrely
369 schema:givenName Véronique
370 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364426744.53
371 rdf:type schema:Person
372 sg:person.01372020723.34 schema:affiliation grid-institutes:None
373 schema:familyName Jary
374 schema:givenName Marine
375 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372020723.34
376 rdf:type schema:Person
377 sg:person.0624575614.78 schema:affiliation grid-institutes:grid.414363.7
378 schema:familyName Baba-Hamed
379 schema:givenName Nabil
380 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624575614.78
381 rdf:type schema:Person
382 sg:person.0635311430.72 schema:affiliation grid-institutes:grid.411162.1
383 schema:familyName Tougeron
384 schema:givenName David
385 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635311430.72
386 rdf:type schema:Person
387 sg:person.0657643442.84 schema:affiliation grid-institutes:grid.411266.6
388 schema:familyName Dahan
389 schema:givenName Laëtitia
390 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657643442.84
391 rdf:type schema:Person
392 sg:person.0724247022.53 schema:affiliation grid-institutes:grid.412370.3
393 schema:familyName André
394 schema:givenName Thierry
395 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724247022.53
396 rdf:type schema:Person
397 sg:person.0777665330.43 schema:affiliation grid-institutes:grid.476348.a
398 schema:familyName Kim
399 schema:givenName Stefano
400 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777665330.43
401 rdf:type schema:Person
402 sg:pub.10.1038/bjc.2015.20 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018025372
403 https://doi.org/10.1038/bjc.2015.20
404 rdf:type schema:CreativeWork
405 sg:pub.10.1186/s12885-017-3566-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091351140
406 https://doi.org/10.1186/s12885-017-3566-0
407 rdf:type schema:CreativeWork
408 grid-institutes:None schema:alternateName Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France
409 schema:name Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France
410 Department of Oncology, University Hospital of Besançon, 3 Boulevard Alexander Flemingn, F-25030 Besançon, France
411 Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France
412 Hôpital Nord Franche Comté, Montbéliard, France
413 INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France
414 rdf:type schema:Organization
415 grid-institutes:grid.139510.f schema:alternateName Centre Hospitalier Universitaire de Reims, Reims, France
416 schema:name Centre Hospitalier Universitaire de Reims, Reims, France
417 rdf:type schema:Organization
418 grid-institutes:grid.411158.8 schema:alternateName Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France
419 Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France
420 schema:name Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France
421 Department of Oncology, University Hospital of Besançon, 3 Boulevard Alexander Flemingn, F-25030 Besançon, France
422 INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France
423 Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France
424 rdf:type schema:Organization
425 grid-institutes:grid.411162.1 schema:alternateName Centre Hospitalier Universitaire de Poitiers, Poitiers, France
426 schema:name Centre Hospitalier Universitaire de Poitiers, Poitiers, France
427 rdf:type schema:Organization
428 grid-institutes:grid.411266.6 schema:alternateName Centre Hospitalier Universitaire La Timone, Marseille, France
429 schema:name Centre Hospitalier Universitaire La Timone, Marseille, France
430 rdf:type schema:Organization
431 grid-institutes:grid.412370.3 schema:alternateName Sorbonne Université and Hôpital Saint Antoine, Paris, France
432 schema:name Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France
433 Sorbonne Université and Hôpital Saint Antoine, Paris, France
434 rdf:type schema:Organization
435 grid-institutes:grid.414093.b schema:alternateName Hôpital Européen Georges-Pompidou, Paris, France
436 schema:name Hôpital Européen Georges-Pompidou, Paris, France
437 rdf:type schema:Organization
438 grid-institutes:grid.414363.7 schema:alternateName Groupe Hospitalier Paris Saint-Joseph, Paris, France
439 schema:name Groupe Hospitalier Paris Saint-Joseph, Paris, France
440 rdf:type schema:Organization
441 grid-institutes:grid.417812.9 schema:alternateName Centre Antoine-Lacassagne, Nice, France
442 schema:name Centre Antoine-Lacassagne, Nice, France
443 rdf:type schema:Organization
444 grid-institutes:grid.418037.9 schema:alternateName Centre Georges-François Leclerc, Dijon, France
445 schema:name Centre Georges-François Leclerc, Dijon, France
446 rdf:type schema:Organization
447 grid-institutes:grid.418116.b schema:alternateName Centre Léon Bérard, Lyon, France
448 schema:name Centre Léon Bérard, Lyon, France
449 rdf:type schema:Organization
450 grid-institutes:grid.418189.d schema:alternateName Centre François Baclesse, Caen, France
451 Institut du Cancer de Montpellier, Montpellier, France
452 schema:name Centre François Baclesse, Caen, France
453 Institut du Cancer de Montpellier, Montpellier, France
454 rdf:type schema:Organization
455 grid-institutes:grid.418596.7 schema:alternateName Institut Curie, Paris, France
456 schema:name Institut Curie, Paris, France
457 rdf:type schema:Organization
458 grid-institutes:grid.42399.35 schema:alternateName Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
459 schema:name Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
460 Fédération Francophone de Cancérologie Digestive (FFCD), Paris, France
461 rdf:type schema:Organization
462 grid-institutes:grid.452351.4 schema:alternateName Centre Oscar Lambret, Lille, France
463 schema:name Centre Oscar Lambret, Lille, France
464 rdf:type schema:Organization
465 grid-institutes:grid.476348.a schema:alternateName Fédération Francophone de Cancérologie Digestive (FFCD), Paris, France
466 schema:name Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France
467 Department of Oncology, University Hospital of Besançon, 3 Boulevard Alexander Flemingn, F-25030 Besançon, France
468 Fédération Francophone de Cancérologie Digestive (FFCD), Paris, France
469 Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France
470 Hôpital Nord Franche Comté, Montbéliard, France
471 INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France
472 rdf:type schema:Organization
473 grid-institutes:grid.492693.3 schema:alternateName Hôpital Privé Jean Mermoz, Lyon, France
474 schema:name Hôpital Privé Jean Mermoz, Lyon, France
475 rdf:type schema:Organization
476 grid-institutes:grid.493837.2 schema:alternateName Cancéropôle Grand-Est, Strasbourg, France
477 schema:name Cancéropôle Grand-Est, Strasbourg, France
478 Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France
479 rdf:type schema:Organization
480 grid-institutes:grid.7429.8 schema:alternateName INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France
481 schema:name INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France
482 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...